81 FR 52452 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 81, Issue 152 (August 8, 2016)

Page Range		52452-52452
FR Document		2016-18689

The invention listed below is owned by an agency of the U.S. Government and is available for licensing and/or co-development in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing and/or co-development.

Federal Register, Volume 81 Issue 152 (Monday, August 8, 2016)

[Federal Register Volume 81, Number 152 (Monday, August 8, 2016)]
[Notices]
[Page 52452]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2016-18689]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Department of Health and Human 
Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing and/or co-development in the 
U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve 
expeditious commercialization of results of federally-funded research 
and development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing and/or co-development.

ADDRESSES: Invention Development and Marketing Unit, Technology 
Transfer Center, National Cancer Institute, 9609 Medical Center Drive, 
Mail Stop 9702, Rockville, MD 20850-9702.

FOR FURTHER INFORMATION CONTACT: Information on licensing and co-
development research collaborations, and copies of the U.S. patent 
applications listed below may be obtained by contacting: Attn. 
Invention Development and Marketing Unit, Technology Transfer Center, 
National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, 
Rockville, MD, 20850-9702, Tel. 240-276-5515 or email 
[email protected]. A signed Confidential Disclosure 
Agreement may be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.
    Title of invention: Synthetic Human-Derived Peptides and 
Peptidomimetics for Cancer Therapeutics
    Keywords: Rpn13, selective proteasome inhibitor, proteasome 
ubiquitin receptors, (competition: carfilzomib and bortezomib too 
toxic, resistance developed), solid tumors, hematological cancer, HPV 
associated cancer, ovarian cancer, prostate cancer, gastric cancer, 
breast cancer, or colorectal cancer
    Description of Technology: FDA approved 26S proteasome inhibitors, 
such as carfilzomib and bortezomib (Velcade[supreg]) have proven to be 
effective at treating hematologic cancers. However, resistance to these 
agents as well as their toxicity have raised concerns and highlight the 
need for new 26S proteasome inhibitors.
    Investigators at the NCI's Structural Biophysics Laboratory have 
developed a new class of proteasome inhibitors. They are hRpn2-derived 
peptides capable of specifically targeting the Pru domain of hRpn13. 
Disruption of the Rpn2/Rpn13 interaction inhibits proteolysis by a 
mechanism that differs from those of the approved proteasome 
inhibitors.
    Potential Commercial Applications:
     New class of proteasome inhibitors, targeting hRpn13 of 
the regulatory particle.
    Value Proposition:
     Synergistic with, and more specific than, known proteasome 
inhibitors.
     Alternate mechanism of action compared to approved 
proteasome inhibitors.
    Development Stage: Discovery (Lead ID).
    Inventor(s): Kylie J. Walters (NCI), Fen Liu (NCI), and Xiuxiu Lu 
(NCI).
    Intellectual Property:
    HHS Reference No. E-278-2015/0-US-01.
    US Provisional Application 62/222,530 (HHS Reference No. E-278-
2015) filed September 23, 2015 entitled ``Human RPN2 Derived Peptides 
Useful For Treating Cancer''.
    Publications: 1. Lu X., et al., 2015 PLoS One 2015 Oct 14;10(10) 
PMID: 26466095.
    Contact Information: Requests for copies of the patent application 
or inquiries about licensing, research collaborations, and co-
development opportunities should be sent to John D. Hewes, Ph.D., 
email: [email protected].

    Dated: July 26, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology Transfer Center, National 
Cancer Institute.
[FR Doc. 2016-18689 Filed 8-5-16; 8:45 am]
 BILLING CODE 4140-01-P

52452 Federal Register / Vol. 81, No. 152 / Monday, August 8, 2016 / Notices

2019, Bethesda, MD 20892, 301–443–2861, development research collaborations, Publications: 1. Lu X., et al., 2015
marmillotp@mail.nih.gov. and copies of the U.S. patent PLoS One 2015 Oct 14;10(10) PMID:
Name of Committee: National Institute on applications listed below may be 26466095.
Alcohol Abuse and Alcoholism Initial obtained by contacting: Attn. Invention Contact Information: Requests for
Review Group; Neuroscience Review Development and Marketing Unit, copies of the patent application or
Subcommittee. Technology Transfer Center, National inquiries about licensing, research
Date: October 27, 2016. collaborations, and co-development
Time: 8:30 a.m. to 5 p.m.
Cancer Institute, 9609 Medical Center
Agenda: To review and evaluate grant Drive, Mail Stop 9702, Rockville, MD, opportunities should be sent to John D.
applications. 20850–9702, Tel. 240–276–5515 or Hewes, Ph.D., email: john.hewes@
Place: National Institute on Alcohol Abuse email ncitechtransfer@mail.nih.gov. A nih.gov.
and Alcoholism, National Institutes of signed Confidential Disclosure Dated: July 26, 2016.
Health, Terrace Level Conference Room 508– Agreement may be required to receive John D. Hewes,
509, 5635 Fishers Lane, Rockville, MD 20852. copies of the patent applications. Technology Transfer Specialist, Technology
Contact Person: Beata Buzas, Ph.D.,
SUPPLEMENTARY INFORMATION: Transfer Center, National Cancer Institute.
Scientific Review Officer, National Institute
On Alcohol Abuse and Alcoholism, National Technology description follows. [FR Doc. 2016–18689 Filed 8–5–16; 8:45 am]
Institutes of Health, 5635 Fishers Lane, Rm. Title of invention: Synthetic Human- BILLING CODE 4140–01–P
2081, Rockville, MD 20852, 301–443–0800, Derived Peptides and Peptidomimetics
bbuzas@mail.nih.gov. for Cancer Therapeutics
(Catalogue of Federal Domestic Assistance Keywords: Rpn13, selective DEPARTMENT OF HEALTH AND
Program Nos. 93.271, Alcohol Research proteasome inhibitor, proteasome HUMAN SERVICES
Career Development Awards for Scientists ubiquitin receptors, (competition:
and Clinicians; 93.272, Alcohol National carfilzomib and bortezomib too toxic, National Institutes of Health
Research Service Awards for Research resistance developed), solid tumors,
Training; 93.273, Alcohol Research Programs; National Cancer Institute; Notice of
hematological cancer, HPV associated
93.891, Alcohol Research Center Grants; Meeting
93.701, ARRA Related Biomedical Research
cancer, ovarian cancer, prostate cancer,
and Research Support Awards, National gastric cancer, breast cancer, or Pursuant to section 10(d) of the
Institutes of Health, HHS) colorectal cancer Federal Advisory Committee Act, as
Description of Technology: FDA amended (5 U.S.C. App. 2), notice is
Dated: August 2, 2016.
approved 26S proteasome inhibitors, hereby given of the meeting of the
Melanie J. Gray, such as carfilzomib and bortezomib National Cancer Advisory Board
Program Analyst, Office of Federal Advisory (Velcade®) have proven to be effective at
Committee Policy.
(NCAB).
treating hematologic cancers. However, The meeting will be open to the
[FR Doc. 2016–18688 Filed 8–5–16; 8:45 am] resistance to these agents as well as public as indicated below, with
BILLING CODE 4140–01–P their toxicity have raised concerns and attendance limited to space available.
highlight the need for new 26S Individuals who plan to attend and
proteasome inhibitors. need special assistance, such as sign
DEPARTMENT OF HEALTH AND Investigators at the NCI’s Structural language interpretation or other
HUMAN SERVICES Biophysics Laboratory have developed a reasonable accommodations, should
National Institutes of Health new class of proteasome inhibitors. notify the Contact Person listed below
They are hRpn2-derived peptides in advance of the meeting. The open
Government-Owned Inventions; capable of specifically targeting the Pru session will be videocast and can be
Availability for Licensing domain of hRpn13. Disruption of the accessed from the NIH Videocasting and
Rpn2/Rpn13 interaction inhibits Podcasting Web site (http://
AGENCY: National Institutes of Health, proteolysis by a mechanism that differs videocast.nih.gov).
Department of Health and Human from those of the approved proteasome A portion of the National Cancer
Services. inhibitors. Advisory Board meeting will be closed
ACTION: Notice. Potential Commercial Applications: to the public in accordance with the
• New class of proteasome inhibitors, provisions set forth in sections
SUMMARY: The invention listed below is targeting hRpn13 of the regulatory 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
owned by an agency of the U.S. particle. as amended. The grant applications and
Government and is available for Value Proposition: the discussions could disclose
licensing and/or co-development in the • Synergistic with, and more specific confidential trade secrets or commercial
U.S. in accordance with 35 U.S.C. 209 than, known proteasome inhibitors. property such as patentable material,
and 37 CFR part 404 to achieve • Alternate mechanism of action and personal information concerning
expeditious commercialization of compared to approved proteasome individuals associated with the grant
results of federally-funded research and inhibitors. applications, the disclosure of which
development. Foreign patent Development Stage: Discovery (Lead would constitute a clearly unwarranted
applications are filed on selected ID). invasion of personal privacy.
inventions to extend market coverage Inventor(s): Kylie J. Walters (NCI), Fen Name of Committee: National Cancer
for companies and may also be available Liu (NCI), and Xiuxiu Lu (NCI). Advisory Board.
for licensing and/or co-development. Intellectual Property: Open: September 7, 2016, 9:00 a.m. to
mstockstill on DSK3G9T082PROD with NOTICES

ADDRESSES: Invention Development and HHS Reference No. E–278–2015/0– 05:00 p.m.
Marketing Unit, Technology Transfer US–01. Agenda: Programs reports and
Center, National Cancer Institute, 9609 US Provisional Application 62/ presentations; business of the Board.
Medical Center Drive, Mail Stop 9702, Place: National Institutes of Health,
222,530 (HHS Reference No. E–278– Building 31, C-Wing, 6th Floor, Room 10,
Rockville, MD 20850–9702. 2015) filed September 23, 2015 entitled 9000 Rockville Pike, Bethesda, MD 20892.
FOR FURTHER INFORMATION CONTACT: ‘‘Human RPN2 Derived Peptides Useful Closed: September 7, 2016, 04:00 p.m. to
Information on licensing and co- For Treating Cancer’’. 05:00 p.m.

VerDate Sep<11>2014 22:23 Aug 05, 2016 Jkt 238001 PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 E:\FR\FM\08AUN1.SGM 08AUN1

Document Created: 2016-08-06 03:08:13
Document Modified: 2016-08-06 03:08:13

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Action		Notice.
Contact		Information on licensing and co- development research collaborations, and copies of the U.S. patent applications listed below may be obtained by contacting: Attn. Invention Development and Marketing Unit, Technology Transfer Center, National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, Rockville, MD, 20850-9702, Tel. 240-276-5515 or email [email protected] A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications.
FR Citation		81 FR 52452

81 FR 52452 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 81, Issue 152 (August 8, 2016)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health